Microbiome Diagnostics Market by Technology, Sample Type, Indication, Service Type, Component, Diagnostic Application, End User - Global Forecast 2026-2032

预计到 2025 年，微生物组诊断市场价值将达到 11.6 亿美元，到 2026 年将成长至 14.1 亿美元，复合年增长率为 21.77%，到 2032 年将达到 46.3 亿美元。

主要市场统计数据
基准年 2025	11.6亿美元
预计年份：2026年	14.1亿美元
预测年份 2032	46.3亿美元
复合年增长率 (%)	21.77%

对微生物组诊断的紧急而详细的介绍：揭示为何技术整合和临床检验正在重新定义诊断护理的途径。

微生物组诊断领域融合了分子科学、临床医学和数位分析技术，正在革新疾病的检测、分层和监测方式。近年来，技术的进步降低了分析门槛，并拓展了可进行可靠分析的生物检体范围。同时，临床和商业相关人员也日益认识到，微生物组既是诊断讯号的来源，也是治疗标靶。因此，诊断流程正从单一分析检测发展为演算法主导的多重评估方法，整合生物学背景、病患病历和纵向监测资料。

快速的技术进步以及监管和商业模式的转变，如何从根本上改变微生物组诊断的基础设施和市场策略？

微生物组诊断领域正经历着一场变革，其驱动力包括技术的成熟、更广泛的临床接受度以及经营模式的转变。定序技术和标靶扩增技术的进步使得从非侵入性检体中提取更丰富、更具临床意义的微生物特征成为可能。同时，生物资讯学的进步也推动了这项技术发展，将原始数据转化为患者层面的解读。因此，诊断开发人员越来越互通性，以确保结果在任何医疗环境中都具有可重复性和可操作性。

评估 2025 年费用修订如何重塑微生物组诊断相关人员的全球采购、供应链策略和采购决策。

2025年实施的新关税措施正在对整个微生物组诊断供应链产生连锁反应，尤其对那些依赖全球采购仪器、耗材和关键试剂的机构而言更是如此。关税导致成本增加，采购团队必须重新评估供应商布局和前置作业时间波动带来的风险，这使得采购变得更加复杂。因此，许多相关人员正在增加缓衝库存并探索多元化采购方案，所有这些都对企业的现金流量和检查室产能规划产生了影响。

详细的细分洞察揭示了技术选择、应用需求、检体类型和最终用户能力如何结合起来，决定商业化和临床部署的路径。

细分市场对于了解整个微生物组诊断生态系统中投资、创新和临床应用的集中方向至关重要。基于技术，市场研究涵盖微阵列、次世代定序和qPCR，其中次世代定序进一步细分为16S rRNA定序、鸟枪法宏基因组学和全基因测序，而qPCR则细分为数位PCR和即时PCR。每种技术方法在分类解析度深度、检测时间和单样本成本之间都存在明显的权衡，这会影响它们在临床和研究中的应用。

详细的区域分析表明，美洲、欧洲、中东和非洲以及亚太地区的法律规范、製造能力和临床生态系统有何不同，以及这些差异对市场准入意味着什么。

在微生物组诊断领域，区域趋势对商业性优先事项、监管互动和商业模式的形成起着至关重要的作用。在美洲，活跃的创业投资资金、集中开展的临床试验以及先进的检测基础设施，都为新诊断技术的快速普及提供了支持；而监管和报销环境则要求企业在临床效用和支付方价值方面，谨慎地构建证据。该地区经常树立商业性标桿，影响全球部署和伙伴关係策略。

策略竞争情报，揭示产品整合、专有分析技术和合作伙伴关係如何决定微生物组诊断生态系统中的竞争优势。

微生物组诊断领域的竞争格局并非由单一主导的经营模式所塑造，而是由产品、服务和分析方法的互补性专业化所决定。儘管主要企业倾向于整合其在耗材、仪器和软体方面的优势，但差异化优势正日益转向专有的生物资讯学、检验的临床演算法以及支持监管申报的完善品质系统。那些投资于标准化检体製备试剂盒和可互通云端平台的企业，能够提供降低诊断检查室和临床合作伙伴进入承包解决方案，从而占据有利地位。

为降低供应链风险、建立生物资讯能力、加速临床检验以及确保与监管机构和保险公司合作提供切实可行的建议。

产业领导企业应采取一系列平衡的策略措施，在应对当前营运瓶颈的同时，建构能够实现长期临床和商业性成功的组织架构。首先，他们应实现关键仪器和耗材采购管道多元化，认证替代供应商以降低关税和物流风险，并优化库存以应对供应衝击。其次，他们应大力投资生物资讯能力和云端分析技术，将复杂的微生物特征转化为临床可解读的输出结果，同时优先推进与电子健康记录系统和实验室资讯管理系统的互通性。

我们高度透明且严谨的调查方法，结合了专家访谈、技术检验、监管审查和供应链分析，为我们的策略结论提供了合法性支持。

支持这些发现的研究结合了第一手和第二手调查方法，以得出平衡且检验的结论。第一手研究包括对临床实验室主任、研究科学家、法规顾问、采购负责人和商业负责人进行结构化访谈，以了解多个地区的实际运作、检验挑战和应用驱动因素。除这些访谈外，专家小组检验了检测流程、资料管道和品管实践，以支持技术假设并解释其临床意义。

简明结论总结了技术、临床检验和营运准备的整合，这将决定微生物组诊断领域的主导者。

微生物组诊断在现代医疗保健中占据着至关重要的地位，它融合了分子层面的精准性、临床决策和个人化治疗路径。从标靶qPCR方法到广泛的全基因组和鸟枪法宏基因组学，技术的多样性为开发者提供了多种可行的途径，每种途径在解析度、处理能力和临床应用性方面各有优劣。这些技术的广泛应用将取决于它们是否能在有意义的适应症中展现临床效用，能否有效控制检体类型在样本製备阶段的差异，以及能否为临床医生和保险公司提供可靠且可重复的分析结果。

目录

第一章：序言

第二章：调查方法

• 调查设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查的前提
• 研究限制

第三章执行摘要

• 首席体验长观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会映射
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 微生物组诊断市场：依技术划分

• 微阵列
• 次世代定序
  • 16S rRNA定序
  • 霰弹枪总体基因体学
  • 全基因组定序
• qPCR
  • 数位PCR
  • 即时PCR

第九章检体类型分類的微生物组诊断市场

• 血
• 航班
• 口腔
• 皮肤
• 尿

第十章 微生物组诊断市场：依适应症划分

• 皮肤病
• 消化系统疾病
• 感染疾病
• 代谢性疾病
• 肿瘤学

第十一章 微生物组诊断市场：依服务类型划分

• 临床实验室服务
• 调查服务

第十二章 微生物组诊断市场：依组件划分

• 消耗品
  • 试剂盒和试剂
  • 检体预处理
• 装置
• 软体与生物资讯学
  • 云端平台
  • 数据分析软体
  • LIMS整合

第十三章 依诊断应用分類的微生物组诊断市场

• 疾病诊断
• 药物发现
  • 生物标记发现
  • 临床试验支持
• 个人化营养
• 风险评估
• 治疗监测

第十四章 微生物组诊断市场：依最终用户划分

• 学术研究机构
• 诊断检测实验室
• 医院和诊所
• 製药和生物技术公司

第十五章 微生物组诊断市场：依地区划分

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十六章 微生物组诊断市场：依组别划分

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十七章 微生物组诊断市场：依国家划分

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十八章：美国微生物组诊断市场

第十九章：中国微生物组诊断市场

第20章 竞争格局

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• 4D Pharma PLC
• Admera Health LLC
• AOBiome Therapeutics
• Atlas Biomed
• BioGaia
• BIOHM Health
• BiomeSense Ltd
• Bione Ventures Private Limited
• CosmosID, Inc.
• DayTwo, Inc.
• Diversigen, Inc.
• DNA Genotek Inc. by OraSure Technologies Inc.
• Enterome
• Ferring Pharmaceuticals
• Finch Therapeutics Group
• Flightpath Biosciences, Inc.
• Genetic Analysis AS
• Genova Diagnostics, Inc.
• International Flavors & Fragrances Inc
• Microba Life Sciences
• Microba Life Sciences Pty Ltd
• Microbial Insights, LLC
• Omnibiome, LLC
• OptiBiotix Health PLC
• Quantbiome, Inc.
• Second Genome, Inc.
• Seres Therapeutics
• Synlogic, Inc.
• Vedanta Biosciences, Inc.
• Viome Life Sciences, Inc.
• Viome, Inc.
• YSOPIA Bioscience

The Microbiome Diagnostics Market was valued at USD 1.16 billion in 2025 and is projected to grow to USD 1.41 billion in 2026, with a CAGR of 21.77%, reaching USD 4.63 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 1.16 billion
Estimated Year [2026]	USD 1.41 billion
Forecast Year [2032]	USD 4.63 billion
CAGR (%)	21.77%

An urgent and nuanced introduction to microbiome diagnostics illuminating why technological integration and clinical validation are redefining diagnostic care pathways

The microbiome diagnostics field sits at the confluence of molecular science, clinical medicine, and digital analytics, and it is reshaping how disease is detected, stratified, and monitored. Recent technological advances have reduced analytical barriers and expanded the range of biological samples that can be reliably profiled, while clinical and commercial stakeholders increasingly recognize the microbiome as both a source of diagnostic signal and a therapeutic target. As a result, diagnostic workflows are evolving from single-analyte tests to multiplexed, algorithm-driven assessments that integrate biological context with patient history and longitudinal monitoring.

This evolution is supported by parallel developments in bioinformatics and laboratory automation that make high-resolution profiling more accessible to diagnostic laboratories and research services. Increasing collaboration among instrument manufacturers, reagent suppliers, and software providers is accelerating end-to-end solutions that promise faster turnaround, improved reproducibility, and more actionable reports for clinicians. Regulatory authorities and payers are beginning to engage on frameworks for analytic validity, clinical utility, and reimbursement pathways, which is helping to move microbiome diagnostics beyond academic validation into real-world clinical adoption. Taken together, these shifts create both immediate commercialization opportunities and medium-term operational challenges for organizations trying to scale.

How rapid technological advances and shifting regulatory and commercial models are driving a fundamental transformation in microbiome diagnostics infrastructure and go-to-market strategies

The landscape for microbiome diagnostics is undergoing transformative shifts driven by technological maturation, broader clinical acceptance, and changing business models. Advances in sequencing modalities and targeted amplification are enabling richer, more clinically relevant microbial signatures to be derived from non-invasive samples, and this technical progress is coupled with greater sophistication in bioinformatics that translates raw data into patient-level interpretation. Consequently, diagnostic developers are increasingly prioritizing interoperability between laboratory instruments, cloud analytics, and electronic health records to ensure results are both reproducible and actionable across care settings.

Concurrently, regulatory and reimbursement frameworks are evolving to address the unique characteristics of microbiome-based tests, prompting companies to invest earlier in clinical utility studies and payer engagement strategies. This regulatory focus, together with rising demand for personalized care, is driving deeper collaboration between diagnostic innovators, clinical research organizations, and therapy developers. Business models are also shifting: service-oriented offerings such as centralized clinical testing services and research services are complementing product sales of consumables and instruments, creating hybrid revenue streams and new commercialization pathways. These dynamics are reshaping competitive advantages, emphasizing speed-to-validation, quality control, and scalable data management.

Assessment of how 2025 tariff changes are reshaping global sourcing, supply chain strategies, and procurement decisions for microbiome diagnostics stakeholders

The introduction of new tariff measures in 2025 has created downstream effects across supply chains that support microbiome diagnostics, particularly for organizations reliant on global sourcing of instruments, consumables, and critical reagents. Tariff-driven cost increases have amplified procurement complexity as purchasing teams reassess supplier footprints and inventory strategies to mitigate exposure to import duties and lead-time volatility. As a result, many stakeholders are increasing buffer stocks and seeking multi-sourcing arrangements, both of which influence operational cash flow and laboratory throughput planning.

In response to these pressures, manufacturers and service providers are exploring localized manufacturing or regional distribution hubs, prioritizing components whose logistics costs are most susceptible to tariff impact. This reconfiguration places a premium on supply chain transparency, quality management, and supplier qualification processes that validate performance parity across alternative sources. Simultaneously, tariffs have accelerated conversations about value engineering in consumables and sample preparation workflows to reduce material intensity without compromising assay sensitivity or specificity. Collectively, these adjustments are influencing capital allocation, contract negotiations, and strategic partnerships as organizations balance near-term cost pressures against the long-term imperative to maintain diagnostic reliability and clinical credibility.

Deep segmentation insights revealing how technology choices, application needs, sample types, and end-user capabilities collectively determine commercialization pathways and clinical adoption

Segment-level differentiation is central to understanding where investment, innovation, and clinical adoption will concentrate across the microbiome diagnostics ecosystem. Based on Technology, market studies encompass Microarray, Next-Gen Sequencing, and Qpcr, with Next-Gen Sequencing further divided into 16S Rrna Sequencing, Shotgun Metagenomics, and Whole Genome Sequencing, and Qpcr subdivided into Digital Pcr and Real-Time Pcr. Each technological pathway presents distinct trade-offs between depth of taxonomic resolution, turnaround time, and cost per sample, which in turn influence where they are deployed clinically and in research.

Based on Diagnostic Application, the landscape addresses Disease Diagnosis, Drug Development, Personalized Nutrition, Risk Assessment, and Therapeutic Monitoring, with Drug Development further studied across Biomarker Discovery and Clinical Trials Support; these application areas drive differing data requirements, regulatory expectations, and clinical validation pathways. Based on Sample Type, profiling of Blood, Fecal, Oral, Skin, and Urine samples requires tailored extraction and stabilization approaches that affect pre-analytic workflows and analytic performance. Based on Indication, focus across Dermatological Conditions, Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, and Oncology determines which biomarkers and assays are prioritized for clinical translation.

Based on End User, the market spans Academic Research Institutes, Diagnostic Laboratories, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies, each with distinct procurement cycles, technical capabilities, and data governance needs. Based on Service Type, offerings are classified as Clinical Testing Services and Research Services, which require different quality management systems and client engagement models. Based on Component, the ecosystem includes Consumables, Instruments, and Software & Bioinformatics, with Consumables further examined through Kits & Reagents and Sample Preparation, and Software & Bioinformatics decomposed into Cloud Platforms, Data Analysis Software, and LIMS Integration. Understanding the interplay among these segment dimensions clarifies why certain technologies are preferred in research versus clinical contexts, how sample type constraints shape assay design, and why end-user capabilities matter when selecting integrated solutions.

A nuanced regional analysis showing how regulatory frameworks, manufacturing capacity, and clinical ecosystems differ across the Americas, Europe Middle East & Africa, and Asia-Pacific and what that means for market entry

Regional dynamics are instrumental in shaping commercial priorities, regulatory engagement, and operational models across the microbiome diagnostics arena. In the Americas, vibrant venture funding, a concentration of clinical trial activity, and advanced laboratory infrastructure support rapid uptake of novel diagnostics, but the regulatory and reimbursement environment requires careful evidence generation focused on clinical utility and payer value. This region often sets commercial standards that influence global rollouts and partnership strategies.

In Europe, Middle East & Africa, heterogenous regulatory regimes and diverse healthcare financing models necessitate flexible go-to-market strategies that account for country-level differences in clinical practice and reimbursement mechanisms. Investment in centralized reference testing services and harmonized data standards can enable broader access across this region. In the Asia-Pacific region, fast-growing research capacity and domestic manufacturing initiatives are creating alternative production hubs and large-scale sample cohorts for validation studies. However, differences in data privacy frameworks, laboratory accreditation, and clinician adoption rates require localized evidence packages and tailored implementation plans. Across all regions, geopolitical factors, local supply chain capabilities, and talent availability will influence whether organizations prioritize local manufacturing, regional partnerships, or global distribution strategies.

Strategic competitive intelligence on how product integration, proprietary analytics, and collaborative partnerships define advantage in the microbiome diagnostics ecosystem

Competitive dynamics in microbiome diagnostics are defined less by a single dominant business model and more by complementary specialization across products, services, and analytics. Leading players tend to integrate strengths across consumables, instruments, and software, but differentiation increasingly comes from proprietary bioinformatics, validated clinical algorithms, and robust quality systems that support regulatory submissions. Companies that have invested in standardized sample preparation kits and interoperable cloud platforms are positioned to offer turn-key solutions that reduce barriers for diagnostic laboratories and clinical partners.

Partnerships and strategic alliances between reagent suppliers, instrument manufacturers, and analytics providers are accelerating time-to-market and increasing the availability of end-to-end validated workflows. At the same time, service providers that offer centralized clinical testing services provide an attractive path to clinical adoption for developers who prefer not to scale laboratory infrastructure. Competitive positioning also depends on the ability to demonstrate clinical utility in targeted indications and to support therapeutic development through biomarker discovery and clinical trial support. Intellectual property around assay chemistries, data processing pipelines, and clinical algorithms plays a moderating role in negotiations, and companies that build transparent validation dossiers and interoperable systems tend to secure broader clinical and commercial uptake.

Actionable recommendations to mitigate supply chain risk, build bioinformatics capability, and accelerate clinical validation while securing regulatory and payer alignment

Industry leaders should pursue a balanced set of strategic actions that address immediate operational constraints while positioning organizations for long-term clinical and commercial success. First, diversify sourcing and qualify alternative suppliers for key instruments and consumables to reduce tariff and logistics exposure, while implementing inventory optimization to smooth supply shocks. Second, invest substantively in bioinformatics capabilities and cloud-based analytics to convert complex microbial signatures into clinically interpretable outputs, and prioritize interoperability with electronic health systems and laboratory information management systems to facilitate adoption.

Third, engage early with regulatory bodies and payers to design evidence generation strategies that demonstrate clinical utility and economic value, and align clinical validation with intended use and reimbursement pathways. Fourth, pursue modular partnership models that combine centralized testing services with localized laboratory enablement, enabling rapid clinical access while building in-country diagnostic capacity. Fifth, standardize pre-analytic workflows and quality control to reduce variability across sample types such as blood, fecal, oral, skin, and urine, and develop companion documentation and training programs for end users including academic institutes, diagnostic laboratories, hospitals, and pharmaceutical companies. Finally, prioritize data governance, patient privacy, and transparent algorithm validation to build clinician trust and support deployment in sensitive indications such as oncology and infectious disease management.

Transparent and rigorous research methodology combining expert interviews, technical validation, regulatory review, and supply chain mapping to support defensible strategic conclusions

The research underpinning these insights combined primary and secondary enquiry methods to ensure balanced, verifiable conclusions. Primary input included structured interviews with clinical laboratory directors, research scientists, regulatory advisors, procurement officers, and commercial leaders to capture operational realities, validation hurdles, and adoption drivers across multiple geographies. These interviews were supplemented by expert panels that reviewed assay workflows, data pipelines, and quality management practices to validate technical assumptions and interpret clinical implications.

Secondary analysis encompassed peer-reviewed literature, regulatory guidance documents, patent landscapes, and public clinical trial registries to triangulate trends in assay development and indication-specific evidence requirements. Supply chain mapping and trade flow analysis were used to assess potential impacts of tariff changes on component sourcing and logistics. Data synthesis included thematic coding of qualitative interviews, cross-validation of technical performance claims, and scenario analysis to stress-test procurement and deployment strategies. Throughout the research process, findings were iteratively validated with subject-matter experts to ensure practical relevance and methodological rigor.

A concise conclusion summarizing the convergence of technology, clinical validation, and operational readiness that will determine which players lead in microbiome diagnostics

Microbiome diagnostics occupies a pivotal space in modern healthcare where molecular precision converges with clinical decision-making and personalized care pathways. Technological diversity-from targeted qPCR approaches to expansive whole genome and shotgun metagenomics-creates multiple viable routes for developers, each with distinct trade-offs in resolution, throughput, and clinical applicability. Adoption will be shaped by the ability to demonstrate clinical utility in meaningful indications, to manage pre-analytic variability across sample types, and to present reproducible analytics that clinicians and payers can trust.

Operational considerations such as supply chain resilience, regional regulatory nuances, and the maturity of local laboratory ecosystems will influence the pace and geography of adoption. Companies that align technical excellence with pragmatic commercialization strategies-combining validated workflows, interoperable analytics, and proactive regulatory engagement-will be best positioned to capture clinician mindshare and to partner effectively with pharmaceutical developers. In short, success will require cross-functional execution that bridges science, regulatory strategy, and commercial deployment in a coordinated manner.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Microbiome Diagnostics Market, by Technology

• 8.1. Microarray
• 8.2. Next-Gen Sequencing
  • 8.2.1. 16S Rrna Sequencing
  • 8.2.2. Shotgun Metagenomics
  • 8.2.3. Whole Genome Sequencing
• 8.3. Qpcr
  • 8.3.1. Digital Pcr
  • 8.3.2. Real-Time Pcr

9. Microbiome Diagnostics Market, by Sample Type

• 9.1. Blood
• 9.2. Fecal
• 9.3. Oral
• 9.4. Skin
• 9.5. Urine

10. Microbiome Diagnostics Market, by Indication

• 10.1. Dermatological Conditions
• 10.2. Gastrointestinal Disorders
• 10.3. Infectious Diseases
• 10.4. Metabolic Disorders
• 10.5. Oncology

11. Microbiome Diagnostics Market, by Service Type

• 11.1. Clinical Testing Services
• 11.2. Research Services

12. Microbiome Diagnostics Market, by Component

• 12.1. Consumables
  • 12.1.1. Kits & Reagents
  • 12.1.2. Sample Preparation
• 12.2. Instruments
• 12.3. Software & Bioinformatics
  • 12.3.1. Cloud Platforms
  • 12.3.2. Data Analysis Software
  • 12.3.3. LIMS Integration

13. Microbiome Diagnostics Market, by Diagnostic Application

• 13.1. Disease Diagnosis
• 13.2. Drug Development
  • 13.2.1. Biomarker Discovery
  • 13.2.2. Clinical Trials Support
• 13.3. Personalized Nutrition
• 13.4. Risk Assessment
• 13.5. Therapeutic Monitoring

14. Microbiome Diagnostics Market, by End User

• 14.1. Academic Research Institutes
• 14.2. Diagnostic Laboratories
• 14.3. Hospitals & Clinics
• 14.4. Pharmaceutical & Biotechnology Companies

15. Microbiome Diagnostics Market, by Region

• 15.1. Americas
  • 15.1.1. North America
  • 15.1.2. Latin America
• 15.2. Europe, Middle East & Africa
  • 15.2.1. Europe
  • 15.2.2. Middle East
  • 15.2.3. Africa
• 15.3. Asia-Pacific

16. Microbiome Diagnostics Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Microbiome Diagnostics Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. United States Microbiome Diagnostics Market

19. China Microbiome Diagnostics Market

20. Competitive Landscape

• 20.1. Market Concentration Analysis, 2025
  • 20.1.1. Concentration Ratio (CR)
  • 20.1.2. Herfindahl Hirschman Index (HHI)
• 20.2. Recent Developments & Impact Analysis, 2025
• 20.3. Product Portfolio Analysis, 2025
• 20.4. Benchmarking Analysis, 2025
• 20.5. 4D Pharma PLC
• 20.6. Admera Health LLC
• 20.7. AOBiome Therapeutics
• 20.8. Atlas Biomed
• 20.9. BioGaia
• 20.10. BIOHM Health
• 20.11. BiomeSense Ltd
• 20.12. Bione Ventures Private Limited
• 20.13. CosmosID, Inc.
• 20.14. DayTwo, Inc.
• 20.15. Diversigen, Inc.
• 20.16. DNA Genotek Inc. by OraSure Technologies Inc.
• 20.17. Enterome
• 20.18. Ferring Pharmaceuticals
• 20.19. Finch Therapeutics Group
• 20.20. Flightpath Biosciences, Inc.
• 20.21. Genetic Analysis AS
• 20.22. Genova Diagnostics, Inc.
• 20.23. International Flavors & Fragrances Inc
• 20.24. Microba Life Sciences
• 20.25. Microba Life Sciences Pty Ltd
• 20.26. Microbial Insights, LLC
• 20.27. Omnibiome, LLC
• 20.28. OptiBiotix Health PLC
• 20.29. Quantbiome, Inc.
• 20.30. Second Genome, Inc.
• 20.31. Seres Therapeutics
• 20.32. Synlogic, Inc.
• 20.33. Vedanta Biosciences, Inc.
• 20.34. Viome Life Sciences, Inc.
• 20.35. Viome, Inc.
• 20.36. YSOPIA Bioscience

LIST OF FIGURES

• FIGURE 1. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL MICROBIOME DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL MICROBIOME DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 13. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 14. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 15. CHINA MICROBIOME DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY 16S RRNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY 16S RRNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY 16S RRNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SHOTGUN METAGENOMICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SHOTGUN METAGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SHOTGUN METAGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY FECAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY FECAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY FECAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SKIN, BY REGION, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SKIN, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SKIN, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DERMATOLOGICAL CONDITIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DERMATOLOGICAL CONDITIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DERMATOLOGICAL CONDITIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 64. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RESEARCH SERVICES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 66. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RESEARCH SERVICES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 67. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RESEARCH SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 68. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
• TABLE 69. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 70. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 71. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 72. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
• TABLE 73. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 74. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 75. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 76. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE PREPARATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 77. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 78. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 79. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 80. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 81. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 82. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 83. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 84. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 85. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
• TABLE 86. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLOUD PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 87. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLOUD PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 88. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLOUD PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 89. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 90. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 91. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 92. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY LIMS INTEGRATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 93. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY LIMS INTEGRATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 94. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY LIMS INTEGRATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 95. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 96. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DISEASE DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 97. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DISEASE DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 98. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DISEASE DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 99. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 100. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 101. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 102. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 103. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 104. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 105. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 106. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 107. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 108. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY CLINICAL TRIALS SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 109. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PERSONALIZED NUTRITION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 110. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PERSONALIZED NUTRITION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 111. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PERSONALIZED NUTRITION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 112. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 113. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 114. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 115. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 116. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 117. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 118. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 119. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 120. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 121. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 122. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 123. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 124. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 125. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 126. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 127. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 128. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 129. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 130. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 131. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 132. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 133. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 134. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 135. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
• TABLE 136. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 137. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 138. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 139. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
• TABLE 140. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
• TABLE 141. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
• TABLE 142. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 143. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 144. AMERICAS MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 145. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 146. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 147. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 148. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
• TABLE 149. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 150. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 151. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 152. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
• TABLE 153. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
• TABLE 154. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
• TABLE 155. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 156. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 157. NORTH AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 158. LATIN AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 159. LATIN AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 160. LATIN AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 161. LATIN AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
• TABLE 162. LATIN AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 163. LATIN AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 164. LATIN AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 165. LATIN AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
• TABLE 166. LATIN AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
• TABLE 167. LATIN AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
• TABLE 168. LATIN AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 169. LATIN AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 170. LATIN AMERICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 171. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 172. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 177. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 178. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
• TABLE 179. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
• TABLE 180. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
• TABLE 181. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 182. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 183. EUROPE, MIDDLE EAST & AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 184. EUROPE MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 185. EUROPE MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 186. EUROPE MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 187. EUROPE MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
• TABLE 188. EUROPE MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 189. EUROPE MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 190. EUROPE MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 191. EUROPE MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
• TABLE 192. EUROPE MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
• TABLE 193. EUROPE MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
• TABLE 194. EUROPE MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 195. EUROPE MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 196. EUROPE MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 197. MIDDLE EAST MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 198. MIDDLE EAST MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 199. MIDDLE EAST MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 200. MIDDLE EAST MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
• TABLE 201. MIDDLE EAST MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 202. MIDDLE EAST MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 203. MIDDLE EAST MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 204. MIDDLE EAST MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
• TABLE 205. MIDDLE EAST MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
• TABLE 206. MIDDLE EAST MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
• TABLE 207. MIDDLE EAST MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 208. MIDDLE EAST MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 209. MIDDLE EAST MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 210. AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 211. AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 212. AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 213. AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
• TABLE 214. AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 215. AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 216. AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 217. AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
• TABLE 218. AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
• TABLE 219. AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
• TABLE 220. AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 221. AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 222. AFRICA MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 223. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 224. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 225. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 226. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
• TABLE 227. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 228. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 229. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 230. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
• TABLE 231. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
• TABLE 232. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
• TABLE 233. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 234. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 235. ASIA-PACIFIC MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 236. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 237. ASEAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 238. ASEAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 239. ASEAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 240. ASEAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
• TABLE 241. ASEAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 242. ASEAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 243. ASEAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 244. ASEAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
• TABLE 245. ASEAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
• TABLE 246. ASEAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
• TABLE 247. ASEAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 248. ASEAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 249. ASEAN MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 250. GCC MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 251. GCC MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 252. GCC MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 253. GCC MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
• TABLE 254. GCC MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 255. GCC MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 256. GCC MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 257. GCC MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
• TABLE 258. GCC MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
• TABLE 259. GCC MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
• TABLE 260. GCC MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 261. GCC MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 262. GCC MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 263. EUROPEAN UNION MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 264. EUROPEAN UNION MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 265. EUROPEAN UNION MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 266. EUROPEAN UNION MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
• TABLE 267. EUROPEAN UNION MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 268. EUROPEAN UNION MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 269. EUROPEAN UNION MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 270. EUROPEAN UNION MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
• TABLE 271. EUROPEAN UNION MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
• TABLE 272. EUROPEAN UNION MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
• TABLE 273. EUROPEAN UNION MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 274. EUROPEAN UNION MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 275. EUROPEAN UNION MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 276. BRICS MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 277. BRICS MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 278. BRICS MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 279. BRICS MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
• TABLE 280. BRICS MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 281. BRICS MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 282. BRICS MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 283. BRICS MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
• TABLE 284. BRICS MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
• TABLE 285. BRICS MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
• TABLE 286. BRICS MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 287. BRICS MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 288. BRICS MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 289. G7 MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 290. G7 MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 291. G7 MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 292. G7 MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
• TABLE 293. G7 MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 294. G7 MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 295. G7 MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 296. G7 MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
• TABLE 297. G7 MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
• TABLE 298. G7 MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
• TABLE 299. G7 MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 300. G7 MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 301. G7 MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 302. NATO MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 303. NATO MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 304. NATO MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 305. NATO MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
• TABLE 306. NATO MICROBIOME DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
• TABLE 307. NATO MICROBIOME DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
• TABLE 308. NATO MICROBIOME DIAGNOSTICS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
• TABLE 309. NATO MICROBIOME DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
• TABLE 310. NATO MICROBIOME DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
• TABLE 311. NATO MICROBIOME DIAGNOSTICS MARKET SIZE, BY SOFTWARE & BIOINFORMATICS, 2018-2032 (USD MILLION)
• TABLE 312. NATO MICROBIOME DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC APPLICATION, 2018-2032 (USD MILLION)
• TABLE 313. NATO MICROBIOME DIAGNOSTICS MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2032 (USD MILLION)
• TABLE 314. NATO MICROBIOME DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 315. GLOBAL MICROBIOME DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 316. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 317. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
• TABLE 318. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY NEXT-GEN SEQUENCING, 2018-2032 (USD MILLION)
• TABLE 319. UNITED STATES MICROBIOME DIAGNOSTICS MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
• TABLE 320.